Core summary of product characteristics for human normal immunoglobulin for subcutaneous and intramuscular use

Current effective version

PDF iconRevision 1 - Adopted guideline

Reference numberCPMP/BPWG/143744/2011 Rev. 1
Effective from01/09/2015
KeywordsHuman normal immunoglobulin, primary immunodeficiency syndromes, hypogammaglobulinaemia, hepatitis A prophylaxis, immunomodulation
DescriptionThis document describes the information to be included in the summary of product characteristics for human normal immunoglobulins for subcutaneous and/or intramuscular administration.

Document history

Revision 1

Current version

PDF iconAdopted guideline

PDF iconOverview of comments

PDF iconDraft guideline

PDF iconConcept paper

In operation: 01/09/2015–present

Published: 26/03/2015

Published: 31/07/2012

Published: 17/12/2010

First version PDF iconAdopted guideline In operation: 01/01/2003–31/08/2015

Related content

How useful was this page?

Add your rating
1 rating